Scoring oral mucositis

Oral Oncology

Volumn 34, Issue 1, 1998, Pages 63-71

  Parulekar, W ^a   Mackenzie, R ^a   Bjarnason, G ^a   Jordan, R C K ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cancer; Chemotherapy; Complications; Mucositis; Oral; Radiotherapy; Scoring

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; DISEASE SEVERITY; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION INJURY; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; HUMANS; MOUTH MUCOSA; RADIOTHERAPY; SEVERITY OF ILLNESS INDEX; STOMATITIS;

EID: 0031922018     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00065-1     Document Type: Article

References (92)

1. [1] Hellman S. Principles of cancer management: radiation therapy. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: Lippincott-Raven, 1997. pp. 307-332.
2. [2] DeVita, VT. Principles of cancer management: chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: Lippincott-Raven, 1997. pp. 333-347.
3. [3] Sonis, ST. Oral complications of cancer therapy. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: JB Lippincott, 1993. pp. 2385-2393.
4. [4] Berger, AM. Kilroy TJ. Oral complications. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: Lippincott-Raven, 1997. pp. 2714-2725.
5. [5] Sanchiz F, Milla A, Tomer J. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. International Journal of Radiation Oncology Biology Physics 1990;19:1347-1350.
6. [6] Browman GP, Cripps C, Hodson DI, Eapen L, Saytha J, Levine MN. Placebo controlled randomized trial of infusion fluorouracil during standard radiotherapy in locally advanced head and neck cancer. Journal of Clinical Oncology 1994;12:2648-2653.
7. [7] Fu KK, Philips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer. Journal of Clinical Oncology 1987;5:1410-1418.
8. [8] Weissberg JB, Son YH, Papac RJ, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology Biology Physics 1989;17:3-9.
9. [9] Bachaud JM, David JM, Boussin G, Daly N. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. International Journal of Radiation Oncology Biology Physics 1991;20:243-246.
10. [10] Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck: the final report of a randomized trial. Cancer 1991;67:915-921.
11. [11] Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. New England Journal of Medicine 1992;327:1115-1121.
12. [12] Salvajoli JV, Morioka H, Trippe N, Kowalski LP. A randomized trial of neoadjuvant vs. concomitant chemotherapy vs. radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. European Archives of Otorhinolaryngology 1992;249:211-215.
13. [13] Haffty BG, Son YH, Sasaki CT, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. International Journal of Radiation Oncology Biology Physics 1993;27:241-250.
14. [14] Smid L, Lesnicar H, Zakotnik B, et al. Radiotherapy combined with simultaneous chemotherapy with mitomycin, and bleomycin for inoperable head and neck cancer - preliminary report. International Journal of Radiation Oncology Biology Physics 1995;32:769-775.
15. [15] Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. Journal of Clinical Oncology 1994;12:385-395.
16. [16] Johnson CR, Schmidt-Ullrich RK, Wazer DE. Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 1992;69:2749-2754.
17. [17] Pinto LHJ, Canary PCV, Araujo CMM, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics 1991;21:557-562.
18. [18] Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiotherapy and Oncology 1992;25:231-241.
19. [19] Maciejewski B, Skladowski K, Pilecki B, et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiotherapy and Oncology 1996;40:137-145.
20. [20] Peters LJ, Ang KK, Thames HD. Altered fractionation schedules. In: Perez CA, Brady LW, editors. Principles and Practice of Radiation Oncology. Philadelphia, JB Lippincott, 1992. pp. 97-113.
21. [21] Hill PR. Cellular basis of radiotherapy. In: Tannock IF, Hill RP, editors. The Basic Science of Oncology. New York: McGraw-Hill, 1992. pp. 259-275.
22. [22] Tannock IF. Biologic properties of anticancer drugs. In: Tannock IF, Hill RP, editors. The Basic Science of Oncology. New York: McGraw-Hill. 1992. pp. 302-316.
23. [23] Terasima R, Tolmach LJ. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 1963;140:490-492.
24. [24] Sinclair WK, Morton RA. X-ray sensitivity during cell generation cycle of cultured Chinese hamster cells. Radiation Research 1966;29:450-474.
25. [25] Chaffey JT, Hellman S. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Research 1971;31:1613-1615.
26. [26] Madoc-Jones H, Mauro F. Age response to X-rays, vinca alkaloids and hydroxyurea of murine lymphoma cells synchronized in vivo. Journal of the National Cancer Institute 1970; 45:1131-1143.
27. [27] Reynolds WR, Hickey AJ, Feldman MI. Dental management of the cancer patient receiving radiation therapy. Clinical Preventive Dentistry 1980;2:5-9.
28. [28] Parsons JT. The effect of radiation on normal tissues of the head and neck. In: Million RR, Cassisi NJ, editors. Management of Head and Neck Cancer: A Multidisciplinary Approach, Vol. 2. Philadelphia: JB Lippincott, 1994, pp. 245-289.
29. [29] Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. British Journal of Radiology 1990;63:554-556.
30. [30] Fleck R, McNeese MD, Ellerbroek NA, Hunter TA, Holmes FA. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. International Journal of Radiation Oncology Biology Physics 1989;17:829-833.
31. [31] Teo P, Tai TH, Choy D. Nasopharyngeal carcinoma with dermatomyositis. International Journal of Radiation Oncology Biology Physics 1989;16:471-474.
32. [32] Olivotto IA, Fairey RN, Gillies JH, Stein H. Fatal outcome of pelvic radiotherapy for carcinoma of the cervix in a patient with systemic lupus erythematosis. Clinical Radiology 1989;40:83-84.
33. [33] Rodriguez R, Fontanesi J, Meyer JL, Vaeth J, Rounsaville M, Vogt P. Normal-tissue effects of irradiation for Kaposi's sarcoma/AIDS. In: Vaeth JM, Meyer JL, editors. Radiation Tolerance of Normal Tissues, Vol. 23. Basel: Karger, 1989. pp. 150-159.
34. [34] Martin CL, Martin JA. In: Low Intensity Radium Therapy. Boston, Little & Brown. 1959, p. 53.
35. [35] Guggenheimer J, Verbin RS, Appel BN, Schmutz J. Clinicothologic effects of cancer chemotherapeutic agents on human buccal mucosa. Oral Surgery 1977;44:58-63.
36. [36] Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991;5:11-18.
37. [37] Sonis A, Sonis S. Oral complications of cancer chemotherapy in pediatric patients. Journal of Pedodontics 1979;3:122-128.
38. [38] Dreizen S, McCredie KB, Bodey GPN, et al. Quantitative analysis of the oral complications of antileukemic chemotherapy. Oral Surgery 1986;62:650-653.
39. [39] Woo SB, Sonis ST, Sonis AL. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer 1990;66:2375-2379.
40. [40] Overholzer CD, Peterson DE, Williams LT, Schimpff SC. Periodontal infection in patients with acute nonlmphocytic leukemia: prevalence of acute exacerbations. Archives of Internal Medicine 1982;142:551-554.
41. [41] Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology 1990;69:437-443.
42. [42] Handbook for Reporting Results of Cancer Treatment, Vol. 48. World Health Organization. Offset publication, Geneva, 1979, pp. 15-22.
43. [43] Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation oral care on the development of oral stomatitis during cancer chemotherapy. Journal of Prosthetic Dentistry 1982;47:181-193.
44. [44] Van Der Schueren EVD, Van Den Bogaert W, Ang KK. Radiotherapy with multiple fractions per day. In: Steel GG, Adams GE, Peckham, MJ, editors. The Biologic Basis of Radiotherapy. Amsterdam: Elsevier, 1983. pp. 195-210.
45. [45] Byfield JE, Frankel SS, Sharp TR, Hornbeck CK, Callipari FB. Phase I and pharmacologic study of 72-hour infused 5-fluoruracil and hyperfractionated cyclical radiation. International Journal of Radiation Oncology Biology Physics 1985;11:791-800.
46. [46] Seto BG, Kim M, Wolinsky L, Mito RS, Champlin R. Oral mucositis in patients undergoing bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1985;60:493-497.
47. [47] Consensus Conference. Oral complications of cancer therapies: diagnosis, prevention and treatment. Connecticut Medicine 1989;53:595.
48. [48] Eilers J, Berger AM, Peterson MC. Development, testing and application of the oral assessment guide. Oncology Nursing Forum 1988;15:325-330.
49. [49] Spijkervet FKL, Van Saene HKF, Panders AK, Vermey A, Mehta DM. Scoring irradiation mucositis in head and neck cancer patients. Journal of Oral Pathology and Medicine 1988; 18:167-171.
50. [50] Wainman N, Paul N, Brundage M, et al. Common toxicity criteria: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) experience. (Abstract). Controlled Clinical Trials 1992;13:435.
51. [51] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology Biology Physics 1995;31:1341-1346.
52. [52] Brundage MD, Pater J, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. Journal of the National Cancer Institute 1993;85:1138-1148.
53. [53] Dische S, Warburton MF, Jones D, Lartigau E. The recording of morbidity related to radiotherapy. Radiotherapy and Oncology 1989;16:103-108.
54. [54] Tardieu C, Cowen D, Thirion X, Franquin JC. Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Oral Oncology, European Journal of Cancer 1996;32B:381-387.
55. [55] Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE. A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplantation 1992;9:409-413.
56. [56] Western Consortium for Cancer Nursing Research. Development of a staging system for chemotherapy-induced stomatitis. Cancer Nursing 1991;14:6-12.
57. [57] Beck S. Impact of a systematic oral care protocol on stomatitis after chemotherapy. Cancer Nursing 1979;2:185-199.
58. [58] Browman GP, Levine MN, Hodson ID, et al. The head and neck radiotherapy questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. Journal of Clinical Oncology 1993;11:863-872.
59. [59] Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplantation 1989;4:89-95.
60. [60] Spijkervet FKL, Van Saene HKF, Panders AK. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67:154-161.
61. [61] Wahlin BY. Effects of chlorhexidene mouthrinse on oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68:279-287.
62. [62] Ferretti AG, Raybould TB, Brown AT, et al. Chlorhexidene prophylaxis for chemotherapy-and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surgery, Oral Medicine, Oral Pathology 1990;69:331-338.
63. [63] Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidene and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73:682-689.
64. [64] Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. Journal of Clinical Oncology 1994;12:2630-2633.
65. [65] Ferraro JM, Mattern JQ. Sucralfate suspension for stomatitis (letter). Drug Intelligence and Clinical Pharmacy 1984;18:153.
66. [66] Ferraro JM. Sucralfate suspension for mouth ulcers (letter). Drug Intelligence and Clinical Pharmacy 1985;19:480.
67. [67] Solomon MA. Oral sucralfate suspension for mucositis. New England Journal of Medicine 1986;315:459-460.
68. [68] Shenep JL, Kalwihsky DK, Hutson PR, et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113: 758-763.
69. [69] Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: a randomized, double-blind cross-over study. Acta Oncologica 1990;29:171-173.
70. [70] Pfeiffer P, Hansen O, Madsen EL, May O. A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity. Acta Oncologica 1990;29:471-473.
71. [71] Scherlacher A, Beaufort-Spontin F. Radiotherapy of head-neoplasms: prevention of inflammation of the mucosa by sucralfate treatment. Head and Neck Oncology 1990;38:24-28.
72. [72] Barker G, Loftus L, Cuddy P, Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1991;71:288.
73. [73] Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology Biology Physics 1994;28:693-698.
74. [74] Kuhrer I, Kuzmits R, Linkesch W, Ludwig H. Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions (letter). Lancet 1986;1:623.
75. [75] Porteder H, Rausch E, Kment G, Waztek G, Matejka M, Sinzinger H. Local prostaglandin E2 in patients with oral malignancies undergoing chemo-and radiotherapy. Journal of Craniomaxillofacial Surgery 1988;16:371-374.
76. [76] Matejka M, Nell A, Kment G, et al. Local benefit of prosplandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral and Maxillofacial Surgery 1990;28:89-91.
77. [77] Labar B, Mrsic M, Pavletic Z, et al. Prostagladin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplantation 1993;11:379-382.
78. [78] Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62:145-148.
79. [79] Pillsbury HC, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology Head and Neck Surgery 1986;112:552-553.
80. [80] Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology Biology Physics 1989;16:1571-1575.
81. [81] Lever SA, Dupuis LL, Chan SL. Comparative evaluation of benzydamine oral rinse, in children with antineoplastic-induced stomatitis. Drug Intelligence and Clinical Pharmacy 1987;21:359-361.
82. [82] Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57:416-417.
83. [83] Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. American Journal of Medicine 1992;92:481-484.
84. [84] Osaki T, Ueta E, Yoneda K, Hirota J, Yamamoto T. Prophylaxis of oral mucositis associated with chemoradiotherapy or oral carcinoma by azelastine hydrochloride (Azelastine) with other antioxidants. Head and Neck Surgery 1994;16:331-339.
85. [85] Sonis ST, Vugt AGV, Brien JPO, et al. Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncology 1997;33:47-54.
86. [86] Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine 1988;318:1414-1422.
87. [87] Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. Journal of Clinical Oncology 1994;12:1917-1920.
88. [88] Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-895.
89. [89] Naylor G, Firmin D, Longmore D. Blood flow imaging by cine magnetic resonance. JCAT 1986;10:715-722.
90. [90] Lieschke GJ, Ramenghi U, O'Connor MP, Sheridan W, Szer J, Morstyn G. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. British Journal of Haematology 1992;82:589-595.
91. [91] Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74:312-317.
92. [92] Williamson RCN, Chir M. Intestinal adaptation (first of two parts): structural, functional and cytokinetic changes. New England Journal of Medicine 1978;298:1393-1402.